Lifeward stock analysis
Want to see LFWD full AI Analyst Report?
Lifeward (LFWD) Stock Price & Analysis
LFWD Stock Chart & Stats
- Day’s Range
- $3.81 - $5.42
- 52-Week Range
- $3.81 - $9.61
- Previous Close
- $5.72
- Volume
- N/A
- Average Volume (3M)
- 17.21K
- Market Cap
- $11.53M
- Enterprise Value
- $30.38M
- Total Cash (Recent Filing)
- $4.55M
- Total Debt (Recent Filing)
- $9.61M
- Price to Earnings (P/E)
- ―
- Beta
- 1.08
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -0.68
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Debt Burden
Low absolute debt and moderate debt-to-equity reduce fixed financial obligations and provide more flexibility than a heavily leveraged balance sheet. If Lifeward improves operations, this structure could leave more room for investment in products, commercial expansion, and rehabilitation technology development.
Established Commercial Reach
A broad distributor network and sizable installed base provide a durable foundation for selling devices, accessories, support, and replacement components. This footprint can improve market access, create customer familiarity, and support adoption of newer products across rehabilitation and mobility categories.
Reimbursement And Product Platform
Reimbursement access can help convert clinical interest into purchases, while a portfolio spanning existing systems and developing products broadens potential revenue sources. Combining commercial infrastructure with robotics, AI, and rehabilitation technologies may support longer-term expansion beyond one device.
Bears Say
Deep Operating Losses
Losses of this magnitude relative to revenue show that the current business has not achieved sustainable operating leverage. Persistent deficits can limit internal funding for product development and commercialization, while requiring substantial improvement in revenue productivity and cost control to stabilize the company.
Material Cash Burn
Negative operating and free cash flow indicate that Lifeward is consuming cash in its ordinary operations rather than funding growth internally. Continued burn at this scale relative to revenue can pressure liquidity over the next several quarters and constrain investment unless profitability or cash generation improves.
Weak Revenue Momentum
Shrinking and inconsistent revenue makes it harder to absorb the company’s fixed operating cost base and demonstrate scalable demand. Without renewed top-line growth, Lifeward may struggle to convert its installed base, reimbursement access, and product pipeline into the volume needed to narrow losses.
Lifeward News
Lifeward’s ReWalk exoskeleton shows sustained long-term home use in study
Lifeward (LFWD) announced the publication of an independent, investigator-initiated peer-reviewed study which provides long-term real-world evidence on the safety, utilization and user experience of the ReWalk Personal Exoskeleton in individuals
Lifeward: Buy Rating Reiterated as Partner-Led Growth Strategy Drives Momentum; 12-Month Price Target Maintained at $10
Lifeward, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $10.00
LFWD FAQ
What was Lifeward’s price range in the past 12 months?
What is Lifeward’s market cap?
When is Lifeward’s upcoming earnings report date?
How were Lifeward’s earnings last quarter?
Is Lifeward overvalued?
Does Lifeward pay dividends?
What is Lifeward’s EPS estimate?
How many shares outstanding does Lifeward have?
What happened to Lifeward’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lifeward?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Lifeward
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Joshua Hexter
- Employees
- 81
- Website
- golifeward.com
- Address
- 3 Hatnufa Street, Yokneam Illit, MA, 2069203, IL
Lifeward (LFWD) Earnings & Revenues
LFWD Earnings Call
Earnings Call SentimentNeutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.
View all LFWD earnings summariesLFWD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 0 | 15 |
| Technical Analysis | 7 | 0 | 3 |
| Moving Averages | 0 | 0 | 12 |












